Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Metastatic Solid Tumors 1Malignant Solid Tumour 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Vorinostat 2nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Hydroxychloroquine 1Dasatinib 1DOXO-EMCH 1Cetuximab 1BN 80927 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Malignant Solid Tumour × DOXO-EMCH × Clear all
NCT01337505 2022-02-10

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

ImmunityBio, Inc.

Phase 1 Completed
24 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡